Stay up to date with our newsletter

Get in touch!

What can we do to help?

I would like to:

Lets start the conversation!

Sign up to our newsletter

View open positions on our Careers page,
or connect with us on Linkedin Twitter Facebook Youtube

Thank you!
We will be in touch shortly.

2020.01.10

Dr. Mark Bittinger joins Sai Life Sciences as Global Head of Biology

Dr. Mark Bittinger

Sai Life Sciences, one of India’s fastest growing Contract Development & Manufacturing Organizations (CDMOs), today announced the appointment of Dr. Mark Bittinger as Vice President and Global Head of Biology. Mark will be based out of the company’s new Discovery Biology facility in Cambridge, Massachusetts, USA, which provides exploratory biology capabilities to the expanding array of start-up and biotech companies in the region.

Mark Bittinger is an acknowledged leader in the area of oncology drug discovery / translational science and has over 25 years of experience across immune-oncology, epigenetics, and tumor cell metabolism. With over 20 research publications to his credit, Mark has had a stellar track record in research, innovation & cross-functional leadership in organizations such as Merck Research Labs, Dana-Farber Cancer Institute, Agios Pharmaceuticals, and Novartis Institute of BioMedical Research. Mark received his B.A. from The Johns Hopkins University and followed with a Ph.D. in Cellular & Molecular Biology from the University of Wisconsin, Madison.

Located in the heart of the Cambridge/Boston biotech ecosystem, Sai’s new 8,500 square feet lab in Kendall Square creates opportunities for biotechs to have face-to-face collaboration with Sai scientists, and to accelerate the pace of their externalized research by reducing cycle-times. The lab provides exploratory biology capabilities using state-of-the-art platforms and technologies such as high-content microscopy, CRISPR-mediated genome editing, flow cytometry/sorting, and high-throughput patch-clamp platforms to address unique client needs. These activities include new target and biomarker identification and/or validation and establishing in vitro and cell-based assays for established targets.

The Cambridge lab serves as a vital bridge, enabling seamless integration with rest of the company’s service offerings across UK and India, spanning the drug discovery and development continuum including medicinal chemistry, DMPK and toxicology, process chemistry and analytical development, and commercial scale manufacturing.

Sai Life Sciences is currently in the midst of an organization-wide initiative, Sai Nxt that is aimed at transforming the company into a new generation CDMO. With investments of over US$150 million between 2019 and 2023, the focus is on three key areas – people & culture, processes & automation, infrastructure & scientific capabilities.

Commenting on his appointment, Mark Bittinger said, " I am incredibly excited to join Sai Life Sciences as we open the doors at our new Cambridge site. Here we will deliver exploratory biology capabilities to accelerate our clients’ ability to build value and deliver tomorrow's medicines."

News

2020.11.20

Sai Life Sciences opens representative office in Tokyo, Japan

Sai Life Sciences opens representative office in Tokyo, Japan

Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRO-CDMO), announced the opening of its representative office in Tokyo, Japan. The new office will serve as base for the company’s outreach to innovator pharmaceutical and biotech companies in Japan and other countries in the Asia Pacific region. A seasoned industry […]
Read more

2020.10.26

Biology, DMPKT & Vivarium

Sai Life Sciences to significantly expand biology capabilities at its integrated R&D campus

Commences construction of new 75,000 sq. ft. facility in Hyderabad Augmenting India team to 170 biologists Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRDMO), today announced plans to significantly expand its biology capabilities at its integrated R&D campus in Hyderabad, India with a dedicated 75,000 sq. ft. facility […]
Read more

2020.10.23

Green Chemistry Awards

Sai Life Sciences introduces Green Chemistry Awards

With the purpose of celebrating and recognizing teams and projects that demonstrate notable work in Green Chemistry, Sai Life Sciences instituted the ‘Green Chemistry Awards’ earlier this year. Using an internally developed computational model, projects were assessed on their ‘Greenness Index’ that is a composite of several attributes across atom & mass efficiency, e-factor, water […]
Read more

2020.10.23

ICH-M7 Services

Comprehensive ICH-M7 assessments for starting materials, intermediates, and final API

Sai Life Sciences offers comprehensive ICH-M7 services to help assess the potential risks of our customers’ starting materials, intermediates, and final API for mutagenicity assessment. As mandated in the ICH M7 guidelines, pharmaceutical companies are now required to assess, identify, and categorize their starting materials, intermediates and final API routes of synthesis and resulting impurities […]
Read more

2020.09.10

Discovery Biology Laboratory in Cambridge, MA, USA

Sai Life Sciences expands suite of cellular analysis platforms in Cambridge, MA

Sai Life Sciences today announced the addition of state-of-the-art cellular analysis platforms at its Discovery Biology facility in Cambridge, Massachusetts, USA. Coinciding with its first anniversary in Cambridge, the expanded suite of capabilities include the Opera Phenix high content screening platform, FACSCelesta flow cytometer and FACSMelody flow sorter, enabling it to better serve start-up and […]
Read more